1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Cosmo Pharmaceuticals N.V.
  6. News
  7. Summary
    COPN   NL0011832936

COSMO PHARMACEUTICALS N.V.

(COPN)
  Report
Delayed Swiss Exchange  -  11:30 2022-06-28 am EDT
47.15 CHF   -0.84%
01:00aCosmo Pharmaceuticals N.V. Announces Acceptance of NDA Submission of Cortiment® Mmx® in Japan
CI
06/21COSMO PHARMACEUTICALS N : June Investor Presentation
PU
06/01COSMO PHARMACEUTICALS N.V. : Ex-dividend day for final dividend
FA
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Cosmo Pharmaceuticals Announces Hiring of Head of Investor Relations and Senior Leadership Change

12/30/2021 | 01:03am EDT

EQS-Ad-hoc: Cosmo Pharmaceuticals N.V. / Key word(s): Miscellaneous
Cosmo Pharmaceuticals Announces Hiring of Head of Investor Relations and Senior Leadership Change

30-Dec-2021 / 06:00 GMT/BST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


Ad hoc announcement pursuant to Art. 53 LR

Dublin, Ireland - 30 December 2021: Cosmo Pharmaceuticals N.V. (SIX: COPN) ('Cosmo') today announced that Ms. Hazel Winchester has been appointed to the position of Head of Investor Relations and will take up the position on the 10th of January, 2022.
 
Ms. Winchester brings almost two decades of investor relations experience. She is a seasoned IR professional who has previously held various positions for a Swiss Medtech and more recently for a SIX-listed biopharmaceutical company. Prior to that, Ms. Winchester worked with different companies in Toronto, Canada, including one which grew from small to large cap listed on the Toronto Stock Exchange and NYSE. She has served on the board of the Canadian Investor Relations Institute (CIRI) and recently joined the board of the IR Club Switzerland.

Alessandro Della Chà, CEO of Cosmo, commented: 'We have been looking for quite some time on how to fill this important role and we believe we have now found in Hazel the right person. I trust she will help us strengthen the relationship with investors at this very important moment in the history of Cosmo'.
 
Cosmo further announced that Mr. Stefano Selva, current CSO, has resigned from Cosmo for personal reasons with effect from the 31st of December 2021. Given the structure and the organization of the R&D Department, the Company does not plan to immediately fill the position.  

Calendar  
Full Year Results 2021 March 31, 2022
Annual General Meeting 2022 May 27, 2022
Half Year Results 2022 July 29, 2022

About Cosmo Pharmaceuticals
Cosmo is a specialty pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders and improve endoscopy quality measures through aiding the detection of colonic lesions. Cosmo develops and manufactures products which are distributed globally including Lialda(R) and Uceris(R)/Cortiment(R). Cosmo has also developed medical devices for endoscopy and has a partnership with Medtronic for the global distribution of GI Genius(TM), its artificial intelligence device, which uses artificial intelligence to help detect potential signs of colon cancer. Cosmo has licensed Aemcolo(R) to Red Hill Biopharma Ltd. for the US and has licensed Relafalk(R) to Dr. Falk Gmbh for the EU and other countries. For additional information on Cosmo and its products please visit the Company's website: www.cosmopharma.com

Contact
Niall Donnelly, CFO 
Cosmo Pharmaceuticals N.V.            
Tel: +353 1 817 03 70
ndonnelly@cosmopharma.com



End of ad hoc announcement
Language: English
Company: Cosmo Pharmaceuticals N.V.
Riverside 2, Sir John Rogerson's
Dublin 2 Dublin
Ireland
Phone: + 353 1 817 0370
E-mail: info@cosmopharma.com
Internet: https://www.cosmopharma.com/
ISIN: NL0011832936
Listed: SIX Swiss Exchange
EQS News ID: 1263320

 
End of Announcement EQS News Service

1263320  30-Dec-2021 GMT/BST

fncls.ssp?fn=show_t_gif&application_id=1263320&application_name=news&site_id=zonebourse_sftp

© EQS 2021
All news about COSMO PHARMACEUTICALS N.V.
01:00aCosmo Pharmaceuticals N.V. Announces Acceptance of NDA Submission of Cortiment® Mmx® in..
CI
06/21COSMO PHARMACEUTICALS N : June Investor Presentation
PU
06/01COSMO PHARMACEUTICALS N.V. : Ex-dividend day for final dividend
FA
05/27COSMO PHARMACEUTICALS N : ' Shareholders approve all Agenda Items at Annual General Meetin..
PU
05/27Cosmo Pharmaceuticals? Shareholders approve all Agenda Items at Annual General Meeting ..
EQ
05/25COSMO PHARMACEUTICALS N : May Investor Presentation
PU
05/03Cosmo Pharmaceuticals, Medtronic Sign Global Distribution Deal for Eleview
MT
05/03Cosmo announces expanding the agreement with medtronic for eleview(r) to all countries ..
EQ
05/03Cosmo Pharmaceuticals N.V. Announces Expanding the Agreement with Medtronic for Eleview..
CI
05/03COSMO PHARMACEUTICALS N : Announces expanding the agreement with medtronic for eleview® to..
PU
More news
Analyst Recommendations on COSMO PHARMACEUTICALS N.V.
More recommendations
Financials
Sales 2022 96,7 M 102 M 102 M
Net income 2022 16,8 M 17,7 M 17,7 M
Net cash 2022 41,8 M 44,0 M 44,0 M
P/E ratio 2022 47,0x
Yield 2022 1,27%
Capitalization 782 M 823 M 823 M
EV / Sales 2022 7,65x
EV / Sales 2023 5,29x
Nbr of Employees 290
Free-Float 48,0%
Chart COSMO PHARMACEUTICALS N.V.
Duration : Period :
Cosmo Pharmaceuticals N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COSMO PHARMACEUTICALS N.V.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 46,80 €
Average target price 85,12 €
Spread / Average Target 81,9%
EPS Revisions
Managers and Directors
Alessandro Della Chà Executive Director
Niall Donnelly Chief Financial Officer
Mauro Severino Ajani Director
Davide Malavasi Director-Qualified Person & Technical
Nhan Ngo Dinh Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
COSMO PHARMACEUTICALS N.V.-27.52%805
JOHNSON & JOHNSON6.56%479 678
ELI LILLY AND COMPANY17.88%293 110
PFIZER, INC.-12.63%289 466
ROCHE HOLDING AG-14.92%272 090
ABBVIE INC.12.51%269 202